breast cancer colorectal cancer
Conditions
Interventions
Resistance and endurance exercise: the CytoFys program.
Patients will participate in a 9 or 12-week resistance and endurance exercise
intervention during chemotherapy. They will be randomly assigned
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with histological confirmed primary colorectal cancer or breast cancer stage II/III aged * 18 years, who will be treated with (neo-)adjuvant or first line chemotherapy.
Exclusion criteria
Exclusion criteria: Patients who are not able to perform basic activities such as walking or biking, who show cognitive disorders or severe emotional instability, who are suffering from other disabling co-morbidity that might hamper physical exercise (e.g. heart failure, chronic obstructive pulmonary disease (COPD), orthopaedic conditions and neurological disorders), and patients who are unable to understand and read the Dutch language will be excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome of measures of this pilot study are: a) Measurements of muscles contractile properties, i.e. muscle force, speed of force development and relaxation, and fatigability. b) Measures of inflammation (CRP, IL-6, TNF-alpha) c) Measures of the insulin pathway (insulin, IGF, C-peptide). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are perceived fatigue, assessed with the Multidimensional Fatigue Inventory (MFI) (60), and health-related quality of life, assessed with the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire C30 (EORTC QL-C30). Sociodemographic factors (e.g. age, gender) will be assessed with questionnaires. Physical activity will also be measured by questionnaire. Cardiorespiratory fitness will be measured using a submaximal exercise test (Chester step test). Upper and lower extremity strength will be measured using a handgrip dynamometer and 30s sit to stand test. Body composition will be assessed by measuring height, weight, hip and waist circumference, and thickness of four skinfolds. These assessments correspond to those used in the Alpe d*HuZes Cancer Rehabilitation (A-CaRe) research programme . Information on clinical variables (e.g. diagnose, tumour stage, treatment and follow-up data including progression free survival (PFS) and overall survival (OS) up to 5 years after diagnosis) will be obtained by medical records. | — |
Countries
Netherlands
Outcome results
None listed